Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
Active, not recruitingOBSERVATIONAL
Enrollment
23
Participants
Timeline
Start Date
March 16, 2023
Primary Completion Date
April 14, 2031
Study Completion Date
April 14, 2031
Conditions
GlaucomaCataractOcular Hypertension
Trial Locations (1)
41101
Centro Oftalmológico Robles, Santa Rosa de Copán
All Listed Sponsors
lead
SpyGlass Pharma, Inc.
INDUSTRY
NCT07154810 - Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination | Biotech Hunter | Biotech Hunter